SanBio Company Limited
Corrected Notice on Domestic Integration of ACGO® Production System Following Minaris USA Factory Closure
In response to Minaris’ US factory closure, ACGO® production will be domestically integrated. Upstream processes will be transferred to the Yokohama Factory to establish a vertically integrated manufacturing system. We will advance dual-track production to enhance manufacturing stability and supply capacity. The impact on this fiscal year's performance is unclear, but there is currently no material impact.
Key Figures
- Domestic integration of ACGO® manufacturing: Mountain View factory closure, transfer of upstream processes to Yokohama factory
- Pilot manufacturing agreement with JCR Pharma Co., Ltd. (aiming for commercial manufacturing)
- Ensured supply stability through secured inventories (details not disclosed)
AI要約
Overview of this matter
SanBio plans to close Minaris' Mountain View factory responsible for ACGO® production and transfer upstream operations to the Yokohama factory in Japan, strengthening a domestically integrated system that handles both upstream and downstream processes. This aims to improve domestic manufacturing stability and supply capacity. Domestic inventories are already secured, so there will be no supply shortage during the transfer period. Additionally, a pilot manufacturing agreement with JCR Pharma has been concluded to pursue commercial manufacturing, promoting dual-track manufacturing.
Future impact and outlook
Through domestic integration and dual-track manufacturing, we are building a production framework to prepare for future US expansion and potential expansion of indications for stroke. At present, the company states there is no material impact on this fiscal year's performance, and any new disclosures will be made promptly as they arise.
SanBio Company Limited
Company overview · Stock price · Financial data · All IR
